The Philadelphia judge overseeing an ongoing Risperdal-related trial has ordered Janssen Pharmaceuticals to turn over by Sunday any documents it may have pertaining to the reanalysis of a key medical report in the litigation, or face possible sanctions.
Philadelphia Court of Common Pleas Judge Kenneth Powell ordered the drug maker to produce all evidence, documents, reports, emails and other nonprivileged information related to a “reanalysis of data” by noon Nov. 15. The order added that, if the deadline is not met, the “custodian” of the items will need to appear Nov. 16 to show why the order was not complied with. Failure to appear will result in sanctions, the order said.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
